Kevin K. Brown

Health Protection Surveillance Centre

Publishes on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases, Sarcoidosis and Beryllium Toxicity Research. 326 papers and 26.9k citations.

PubIndex Score98Top 2%How it's scored

🌟#9 Current Senior Leader in Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

326Publications

26.9kTotal Citations

#9in Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

First publication: 1982First senior author: 2003

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Systemic Sclerosis and Related Diseases Sarcoidosis and Beryllium Toxicity Research Medical Imaging and Pathology Studies Chronic Obstructive Pulmonary Disease (COPD) Research

Top publicationsby citations

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Kevin R. Flaherty, Kevin K. Brown, Athol U. Wells et al.|New England Journal of Medicine|2019

Cited by 2.3k

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Francis X. McCormack, Bruce C. Trapnell, Yoshikazu Inoue et al.|New England Journal of Medicine|2011

Cited by 1.1k

Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis

Harold R. Collard, Kevin K. Brown, Talmadge E. King et al.|American Journal of Respiratory and Critical Care Medicine|2003

Cited by 762

A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis

Ganesh Raghu, Talmadge E. King, Kevin K. Brown et al.|New England Journal of Medicine|2004

Cited by 652

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Daniel F. Dilling, Bruno Crestani et al.|The Lancet Respiratory Medicine|2020

Cited by 558